%0 Journal Article
%T Being diagnosed with a rhabdomyosarcoma in the era of artificial intelligence: Whom can we trust?
%A Clerici CA
%A Bernasconi A
%A Lasalvia P
%A Bisogno G
%A Milano GM
%A Trama A
%A Chiaravalli S
%A Bergamaschi L
%A Casanova M
%A Massimino M
%A Ferrari A
%J Pediatr Blood Cancer
%V 0
%N 0
%D 2024 Aug 11
%M 39129151
%F 3.838
%R 10.1002/pbc.31256
%X In the era of big data, young patients may be overwhelmed by artificial intelligence-based tools, like chatbots. Five clinical experts were asked to evaluate the performance of the most currently used chatbots in providing information on a rare cancer affecting young people, like rhabdomyosarcoma. Generally speaking, despite their high performance in giving general information about the disease, these chatbots were considered by the experts to be inadequate in providing suggestions on cancer treatments and specialized centers, and also lacking in "sensitivity." Efforts are planned by the pediatric oncology community to improve the quality of data used to train these tools.